Emergent Biosolutions Inc. Stock
Emergent Biosolutions Inc. shows a slight decrease today, losing -€0.028 (-0.300%) compared to yesterday.
Emergent Biosolutions Inc. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 13 € there is a positive potential of 40.03% for Emergent Biosolutions Inc. compared to the current price of 9.28 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -0.300% | 2.767% | -8.170% | 35.691% | -10.645% | -28.552% | -88.609% |
| Iovance Biotherapeutics Inc. | 31.310% | 44.357% | 43.418% | -39.647% | 34.802% | -51.859% | -90.116% |
| United Therapeutics | 0.650% | -1.326% | 1.311% | 17.280% | -5.968% | 69.679% | 180.979% |
| Neurocrine Bioscience | 1.740% | 3.106% | -3.472% | -2.285% | -8.890% | 14.486% | 22.440% |
Comments
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat